SHINIL Pharma Ltd (SiPL) is a rapidly growing pharmaceutical company in the Human Health and Animal Health sector in Bangladesh. With a strong commitment to quality, SiPL utilizes the latest technology to formulate and produce generic formulations that meet international standards. Established in 1995 as PHARMA & FIRM in association with SHINIL BIOGEN Co., Ltd, SiPL initially focused on importing and distributing SHINIL products in the local market.

In 2006, SiPL decided to establish its own pharmaceutical plant to produce imported products from SHINIL BIOGEN CO., Ltd, Korea, as well as local generics for the indigenous market. Operating under cGMP and WHO guidelines, SiPL's state-of-the-art manufacturing facility ensures the highest quality standards. The company's distribution network, supported by strategically located depots and a highly skilled marketing team, facilitates efficient product distribution.

SiPL is dedicated to continuous improvement and innovation, conducting extensive in-house research to enhance product efficacy and meet the needs of prescribers, patients, chemists, and retailers. SiPL offers a wide range of healthcare and animal health products, and plans to expand its product portfolio to include vaccines, hormones, and cephalosporin preparations in the future. Through a strategic marketing process, SiPL aims to build strong customer relationships and deliver superior customer value.

With a focus on skilled personnel, effective resource allocation, and strategic decision-making, SiPL is committed to implementing successful strategies at all levels of the organization